glp 1 small molecule Companies seek a second obesity treatment revolution—in pill form | Science Drug Hunter's 2023 Patent Review
Description
Manufacturing scale matters toobrand facilities produce millions of doses annually in specialized factories with redundant quality systems, backup supply chains, and insurance costs that compounding pharmacies don't require
Regular monitoring by a healthcare provider proves essential to manage these risks effectively
Tatum, PsyD, MS, of the VCU School of Public Health
(overview), GLP-1 Receptor Agonist
